Genprex (LTS:0A8I) Debt-to-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Genprex Debt-to-Asset?

Genprex's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. Genprex's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. Genprex's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $4.12 Mil. Genprex's debt to asset for the quarter that ended in Dec. 2024 was 0.00.

Genprex Debt-to-Asset Historical Data

The historical data trend for Genprex's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genprex Debt-to-Asset Chart

Genprex Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

Genprex Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Genprex's Debt-to-Asset

For the Biotechnology subindustry, Genprex's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genprex's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genprex's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Genprex's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Genprex Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Genprex's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	4.124
	=	0.00

Genprex's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	4.124
	=	0.00

Genprex (LTS:0A8I) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Genprex Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Genprex's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Genprex Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genprex Inc (LTS:0A8I) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

GNPX:USA

Address

3300 Bee Cave Road, Suite 650-227, Austin, TX, USA, 78746

Website

https://www.genprex.com

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Genprex Headlines

No Headlines